EUCTR2012-000437-39-NL进行中（未招募）不适用
A randomized study with Cisplatinum or Cetuximab and standard or adaptive high dose radiotherapy for advanced head and neck cancer. - ARTFORCE Head and Neck cancer study
ederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)0 个研究点目标入组 268 人开始时间: 2012年3月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 268
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Squamous cell carcinoma of the oropharynx, oral cavity or hypopharynx
- •- Stage III-IV, T3-4, Nx M0
- •- Age 18 to 70 yrs
- •- GFR >60
- •- informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 168
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •- Inability to undergo any one of the treatment arms
- •- Laryngeal cancer
- •- Known active symptomatic infections
- •- Prior surgery, radiotherapy or chemotherapy for this tumour
研究者
相似试验
进行中（未招募）
不适用
Randomized, controlled trial of Platinum-Cetuximab combined either withDocetaxel (TPEx) or with 5FU (Extreme) in patients withrecurrent/metastatic squamous cell cancer of the head and neckrecurrent or metastatic head and neck squamous cell carcinomaMedDRA version: 17.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000048-14-ESGORTEC416
撤回
2 期
Cisplatin or Cetuximab and conventional versus redistributed radiation for advanced head and neck cancerOropharyngeal cancer1003866610046304head and neck cancerNL-OMON36211ederlands Kanker Instituut
进行中（未招募）
1 期
Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma.EUCTR2009-014293-17-BEniversity Hospital Ghent18
进行中（未招募）
不适用
Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma.Patients with malignant pleural mesotheliomaMedDRA version: 13.1Level: PTClassification code 10059518Term: Pleural mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014293-17-NLAtrium MC Parkstad18
已完成
2 期
Phase II study of Cetuximab combined with Cisplatin or Carboplatin/Pemetrexed as first line treatment in patients with malignant pleural mesotheliomamalignant mesothelioma or cancer of the mesothelium10027412NL-OMON34616Atrium MC Heerlen10